Global Dengue Vaccine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Análise de mercado de vacinas contra a dengue

O mercado das vacinas contra a dengue está a registar um crescimento significativo devido à crescente incidência da dengue em todo o mundo. Esta infeção viral transmitida por mosquitos representa um grande desafio de saúde pública, particularmente nas regiões tropicais e subtropicais. O mercado é impulsionado pela crescente consciencialização sobre os cuidados de saúde preventivos e pela necessidade de uma vacinação eficaz para conter a propagação da doença. Os desenvolvimentos recentes incluem a aprovação e o lançamento de vacinas inovadoras, como a Dengvaxia e a Qdenga, que oferecem uma protecção eficaz contra múltiplos serotipos do vírus da dengue. Espera-se que o crescente investimento em investigação e desenvolvimento por parte das empresas farmacêuticas, juntamente com as iniciativas governamentais para promover campanhas de vacinação, melhore ainda mais a expansão do mercado. À medida que as viagens globais aumentam e as alterações climáticas afectam as populações de mosquitos, prevê-se que a procura de vacinas contra a dengue aumente, apresentando oportunidades significativas para os intervenientes no mercado e as partes interessadas no sector da saúde.

Tamanho do mercado de vacinas contra a dengue

O tamanho do mercado global de vacinas contra a dengue foi avaliado em 592,01 milhões de dólares em 2023 e deverá atingir 1.434,67 milhões de dólares até 2031, com um CAGR de 11,70% durante o período de previsão de 2024 a 2031. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços e enquadramento regulamentar.

Tendências do mercado de vacinas contra a dengue

“ Adoção crescente de programas de vacinação contra a dengue”

O mercado das vacinas contra a dengue está a testemunhar tendências notáveis ​​impulsionadas pelo aumento da consciencialização e pela crescente incidência da dengue em todo o mundo. As inovações no desenvolvimento de vacinas, como a introdução de vacinas tetravalentes que protegem contra os quatro serotipos do vírus da dengue, estão a melhorar a eficácia e os perfis de segurança. Uma tendência significativa é a crescente adopção de programas de vacinação contra o dengue nas regiões endémicas, particularmente no Sudeste Asiático e na América Latina, onde as autoridades de saúde estão a dar prioridade a medidas preventivas. Além disso, a colaboração entre as empresas farmacêuticas e os governos está a promover a distribuição acelerada e a acessibilidade das vacinas. À medida que o mercado evolui, a ênfase em estratégias de vacinação abrangentes e no envolvimento da comunidade será fundamental no controlo dos surtos de dengue e na melhoria dos resultados de saúde pública.

Âmbito do relatório e segmentação do mercado de vacinas contra a dengue     

Definição de mercado de vacinas contra a dengue

A vacina contra a dengue é um produto médico desenvolvido para prevenir a dengue, uma infeção viral transmitida por mosquitos. A vacina estimula o sistema imunitário a produzir anticorpos contra o vírus da dengue, o que pode reduzir a gravidade da doença ou prevenir completamente a infeção. As vacinas contra a dengue têm normalmente como alvo todos os quatro serotipos do vírus, uma vez que a infeção por um serotipo não confere imunidade contra os outros.

Dinâmica do mercado de vacinas contra a dengue

Motoristas

• Aumento da incidência de dengue

A crescente incidência de surtos de dengue em todo o mundo, especialmente nas regiões tropicais e subtropicais, alimenta significativamente a procura de uma vacinação eficaz como medida preventiva. Estes surtos tornaram-se mais frequentes devido a fatores como as alterações climáticas, a urbanização e o crescimento populacional, levando a condições ideais de reprodução dos mosquitos Aedes, transmissores do vírus da dengue. Como resultado, mais pessoas estão a tomar consciência da potencial gravidade da dengue, incluindo a sua capacidade de causar complicações graves e até a morte. Este crescente reconhecimento dos riscos da doença está a levar os governos e as organizações de saúde a dar prioridade aos programas de vacinação como estratégia fundamental para controlar os surtos. Consequentemente, a necessidade de vacinas seguras e eficazes contra a dengue está a aumentar, impulsionando o crescimento do mercado e atraindo investimentos em investigação e desenvolvimento.

• Iniciativas Governamentais e Financiamento

O aumento do financiamento governamental para as iniciativas de prevenção e vacinação da dengue, juntamente com as políticas e regulamentos de apoio, desempenha um papel crucial na condução do crescimento do mercado. Reconhecendo a ameaça à saúde pública que a dengue representa, os governos das regiões endémicas estão a afectar mais recursos para combater a doença através de programas de vacinação. Estes fundos são utilizados para reforçar os esforços de investigação e desenvolvimento, permitindo a criação de vacinas mais eficazes. Além disso, os quadros regulamentares de apoio simplificam o processo de aprovação de novas vacinas, facilitando uma entrada mais rápida no mercado. Os governos estão também a lançar campanhas de sensibilização pública para educar as comunidades sobre os benefícios da vacinação, impulsionando ainda mais a procura. Este compromisso com a prevenção da dengue melhora os resultados em saúde e incentiva as empresas farmacêuticas a investir em soluções inovadoras, alargando assim o panorama do mercado das vacinas contra a dengue.

Oportunidades

• Desenvolvimento de vacinas inovadoras

The ongoing advancements in vaccine technology, particularly in areas such as mRNA and viral vector platforms, present substantial opportunities for the development of more effective and safer dengue vaccines. These innovative technologies allow for a more targeted immune response, potentially enhancing the immunogenicity of vaccines and providing longer-lasting protection against the dengue virus. The ability to rapidly design and modify vaccines using these platforms means that manufacturers can respond more swiftly to emerging strains and outbreaks. Furthermore, the incorporation of novel adjuvants and delivery methods can further improve vaccine efficacy and safety profiles. As research continues to unfold in this arena, there is a significant potential to create vaccines that prevent dengue and minimize adverse reactions, thereby boosting public confidence and uptake.

• Rising Awareness and Education in Dengue Vaccination

Increased public awareness regarding the significance of dengue vaccination, particularly in endemic regions, presents a valuable opportunity for boosting vaccine uptake. Educational campaigns aimed at informing communities about the dangers of dengue and the benefits of vaccination can play a crucial role in encouraging participation in vaccination programs. By disseminating information through various channels—such as social media, community health workshops, and partnerships with local healthcare providers—public health organizations can effectively engage populations at risk. This heightened awareness fosters a sense of community responsibility and empowers individuals to make informed health choices. As communities become more proactive about dengue prevention, the demand for vaccines is likely to rise, consequently driving market growth and contributing to improved public health outcomes.

Restraints/Challenges

• Cost of Vaccination Programs

The financial burden of implementing vaccination programs, particularly in low-income countries, poses a significant challenge to the dengue vaccine market. Many governments operate within limited budgets, which may restrict their capacity to launch comprehensive vaccination initiatives. These financial constraints can lead to inadequate funding for public health campaigns, affecting vaccine accessibility and distribution. Furthermore, the costs associated with vaccine procurement, storage, and administration add additional strain on already stretched healthcare budgets. As a result, low-income regions may experience delays in vaccine rollout, limiting the population's access to essential preventive measures against dengue fever. Consequently, this financial barrier can hinder overall market growth and effectiveness in combating dengue outbreaks, underscoring the need for sustainable funding solutions.

• Distribution and Cold Chain Logistics

Vaccines typically require refrigeration to preserve their efficacy, which can be particularly difficult to achieve in remote or low-resource areas where infrastructure may be lacking. In many developing regions, inadequate cold chain systems can hinder the effective distribution of dengue vaccines, leading to potential spoilage or loss of potency during transit. This logistical challenge affects vaccine availability and raises concerns about vaccine safety and efficacy, ultimately impacting public trust in vaccination programs. Addressing these cold chain infrastructure issues is crucial for ensuring that dengue vaccines reach the populations that need them most, thereby limiting their impact on overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Dengue Vaccine Market Scope

The market is segmented on the basis of type, treatment, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Live Attenuated Vaccine
• Chimeric Live Attenuated Vaccine
• Inactivated Vaccine
• Subunit Vaccine
• Nucleic Acid Based Vaccine

Treatment

• Diuretic
• Anti-Allergic
• Blood Thinners
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Dengue Vaccine Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the market due to the presence of key industry players. In addition, the rising incidence of dengue cases in the region has further fueled market expansion. This combination of factors positions North America as a key player in the ongoing development and distribution of dengue vaccines.

The Asia-Pacific region leads the dengue vaccine market, primarily due to heightened government spending aimed at improving healthcare infrastructure. This increased investment facilitates the development and distribution of advanced healthcare solutions, including vaccines. As a result, the region is well-positioned to address the growing demand for effective dengue prevention measures.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Dengue Vaccine Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Dengue Vaccine Market Leaders Operating in the Market Are:

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• BIO-MED (India)
• Intercept Pharmaceuticals, Inc. (U.K.)
• Emcure Pharmaceuticals Ltd (India)
• Changchun BCHT Biotechnology Co. (China)
• Novo Medi Sciences Pvt. Ltd. (India)

Latest Developments in Dengue Vaccine Market

• In February 2024, Takeda and Biological E announced a collaboration to produce 50 million dengue vaccines, enhancing efforts to combat the disease. In addition, Miltenyi Biotec unveiled the Hyderabad Center for Cell and Gene Therapy Services, focusing on advanced therapeutic solutions. The BioAsia 2024 event showcased significant breakthroughs in the pharmaceutical industry, highlighting innovations and advancements in healthcare
• In April 2023, health authorities in Argentina approved the use of a Japanese dengue vaccine, which requires administration in two doses spaced three months apart. This decision marks a significant step in enhancing dengue prevention efforts within the country. The two-dose regimen is designed to ensure optimal immunity against the disease
• In May 2023, Takeda announced that its dengue vaccine, QDENGA®, received multiple approvals, including one from Brazil's National Health Surveillance Agency in March 2023. This approval permits the vaccine's use in individuals aged 4 to 60 years, offering protection against all four dengue virus serotypes. Takeda's advancements in securing these approvals demonstrate its ongoing efforts to combat dengue fever effectively
• In March 2021, Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate, TAK-003, received approval from the European Medicines Agency (EMA) for use in preventing outbreaks among individuals aged 4 to 60. The company plans to seek regulatory approvals for this vaccine in several countries, including Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand throughout 2021. This move reflects Takeda's commitment to expanding access to dengue prevention globally

SKU-57455